Table 2.
The differences between patients with PR3 and MPO positive vasculitis, showing demographics, induction treatment, relapse, and mortality results associated with each cohort.
| Demographics | Total | PR3 | MPO |
| (n=43) | (n=19) | (n=24) | |
| Age, years (SD) | 65.9 (±11.06) | 58.8 (±10.75) | 71.6 (±7.97) |
| Sex (M:F) | 20:23 | 9:10 | 11:13 |
| eGFR at diagnosis, median (IQR), ml/min | 18 (10.5–27.5) | 19 (9–28) | 18 (12.5–26.3) |
| Induction treatment | |||
| Plasma exchange | 12 | 8 | 4 |
| IV methylprednisolone | 16 | 7 | 9 |
| Cyclophosphamide | 39 | 17 | 22 |
| Rituximab | 4 | 2 | 2 |
| Cumulative steroid dose, mg, median (IQR) | |||
| 1 month | 1260 (1032.5–2380) | 1365 (1032.5–2487.5) | 1155 (1042–2115) |
| 6 months | 3870 (2826.3–4412.5) | 4060 (3432.5–4502.5) | 3360 (2795–4200) |
| 1 year | 4970 (4000–5555) | 5247 (4660–5587.5) | 4340 (3698.8–5357.5) |
| 2 years | 6795 (5092.5–7724) | 7072 (6485–7856.5) | 5291.3 (4678.5–7337.8) |
| 4 years | 9072 (5565–11126) | 9330.5 (8121.8–11,109.5) | 5665 (5223–11407.5) |
| Patients scoring on the composite GTI list, n (%) | |||
| 1 month | 3 (7.0) | 1 (5.3) | 2 (8.3) |
| 6 months | 14 (35) | 7 (36.8) | 7 (32) |
| 1 year | 20 (51.3) | 11 (57.9) | 9 (42.9) |
| 2 years | 26 (66.7) | 14 (73.7) | 13 (61.9) |
| 4 years | 27 (71.1) | 14 (73.7) | 13 (65) |
| Relapsed disease, n | 8 | 5 | 3 |
| ESRF, n | 2 | 2 | 0 |
| Mortality, n | 5 | 0 | 5 |
Cumulative steroid doses are demonstrated as median cumulative doses with interquartile range in milligrams. In addition, the number of patients suffering for glucocorticoid-related toxicity at separate time intervals are also shown. Percentages of patients scoring for features of glucocorticoid toxicity as per the composite list in the Glucocorticoid Toxicity Index are presented. All percentages are calculated on the basis of the number of patients alive at each time point. M, male; F, female; IV, intravenous; GTI, Glucocorticoid Toxicity Index; ESRF, end stage renal failure.